Trial · NCT04105504
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline Spot UV at 4 weeks | 4 weeks | Total reduction (improvement) of spot UV |
| Primary | Change from Baseline Spot Polarization at 4 weeks | 4 weeks | Total reduction (improvement) of spot polarization |
| Primary | Change from Baseline Skin Tone at 4 weeks | 4 weeks | Improvement of skin tone |
| Primary | Change from Baseline Spot UV at 8 weeks | 8 weeks | Total reduction (improvement) of spot UV |
| Primary | Change from Baseline Spot Polarization at 8 weeks | 8 weeks | Total reduction (improvement) of spot polarization |
| Primary | Change from Baseline Skin Tone at 8 weeks | 8 weeks | Improvement of skin tone |
| Primary | Change from Baseline Spot UV at 12 weeks | 12 weeks | Total reduction (improvement) of spot UV |
| Primary | Change from Baseline Spot Polarization at 12 weeks | 12 weeks | Total reduction (improvement) of spot polarization |
| Primary | Change from Baseline Skin Tone at 12 weeks | 12 weeks | Improvement of skin tone |
| Secondary | Subjective Improvement at 4 weeks | 4 weeks | Subjects were asked to grade the overall response using rating scale with a multiple-choice question: 1. minimal improvement 2. moderate improvement 3. good improvement 4. excellent improvement Note: The higher improvement represents a better outcome. |
| Secondary | Adverse events at 4 weeks | 4 weeks | Adverse events related to therapy |
| Secondary | Subjective Improvement at 8 weeks | 8 weeks | Subjects were asked to grade the overall response using rating scale with a multiple-choice question: 1. minimal improvement 2. moderate improvement 3. good improvement 4. excellent improvement Note: The higher improvement represents a better outcome. |
| Secondary | Adverse events at 8 weeks | 8 weeks | Adverse events related to therapy |
| Secondary | Subjective Improvement at 12 weeks | 12 weeks | Subjects were asked to grade the overall response using rating scale with a multiple-choice question: 1. minimal improvement 2. moderate improvement 3. good improvement 4. excellent improvement Note: The higher improvement represents a better outcome. |
| Secondary | Adverse events at 12 weeks | 12 weeks | Adverse events related to therapy |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04105504/registered